Natco Pharma will be raising Rs 153 crore from CX Securities, a foreign institutional investor. The board of directors of the company at its meeting held on October 19, 2013 has approved to issue 24 lakh equity shares of Rs 10 each to CX Securities on a preferential basis. The shares will be issued at a price of Rs 638.40 apiece, aggregating to Rs 153 crore, subject to the necessary approvals. The proceeds of the issue will be used for general corporate purposes.
Besides, the company also plans to increase the limit of NRIs/PIOs (non-resident Indians/persons of Indian origin) and FIIs to 24-49 percent of the paid-up capital of the company. An extraordinary general meeting of the company will be held on November 14 to consider the proposals.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1619.95 |
| Dr. Reddys Lab | 1315.85 |
| Cipla | 1294.75 |
| Zydus Lifesciences | 927.15 |
| Lupin | 2296.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: